News

Polyphor Ltd and Axxam SpA Announce Ion Channel Collaboration Polyphor Ltd – a clinical stage biotech company applying its proprietary drug discovery research platforms to address protein-protein interactions and other challenging targets and Axxam SpA – a leading company in conducting early-stage discovery research programs for the life science industry, are pleased to announce a […]

Axxam Receives US Patent for Innovative Technology Photina® Axxam is pleased to announce the award of US Patent number US 7,601,805 B2, entitled “Photoprotein with improved bioluminescence”, describing the company’s proprietary photoprotein known as Photina®. The invention provides a chimeric photoprotein with improved luminescent activity and its use as a calcium indicator in reporter gene

Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes Fast Forward, LLC, the commercial drug development arm of the National Multiple Sclerosis Society, and the Juvenile Diabetes Research Foundation (JDRF), the leader in research leading to a cure for type 1

Dompé farmaceutici and Axxam Announce the Extension of Their Drug Discovery and Development Collaboration Dompé farmaceutici SpA and Axxam SpA announced today the renewal of the existing research collaboration for the discovery and development of novel drugs based on GPCRs and ion channel targets. Scientists from both companies will continue their joint programs for the

CyBio and Axxam Develop a New System for High Throughput Screening – Expanding Capabilities in Robotic HTS CyBio AG (www.cybio-ag.com), a worldwide leading life science company, and Axxam SpA, a leading discovery company, announce that they have developed, installed and fully validated a new state-of-the-art screening station to be used by Axxam in running hit

InterMed Discovery GmbH and Axxam SpA Announce Joint Research Agreement for the Identification of Novel Natural Functional Ingredients InterMed Discovery (IMD), an emerging world class natural product lead-discovery company, and Axxam, a leading discovery company, are pleased to announce that their joint research efforts have proved to be successful in providing a technology platform that

Axxam awarded substantial funding by the Regione Lombardia (Metadistretti) to support an innovative drug discovery project Axxam announced that a consortium led by Axxam spa has been awarded a grant of EUR 1 million from the Regione Lombardia (Metadistretti) towards a EUR 2.5 million R&D program aimed at identifying and developing innovative Nav 1.7 sodium

Axxam announces the acquisition of molecular screening technologies and related intellectual property rights from Bayer HealthCare AG Axxam, a leading science-driven biotechnology company which provides early-stage discovery research for the life science industry, has signed an agreement for the acquisition of molecular screening technologies and related patent rights from Bayer HealthCare AG. The Bayer technologies

Genedata and Axxam Announce High Throughput Screening Data Analysis Collaboration Genedata, the leading provider of in silico solutions for the pharmaceutical and life science industries, and Axxam, a leading biotechnology research organization offering early-stage discovery research services for the life science industry, have signed a multi-year contract for the implementation of the Genedata Screener®data analysis

Axxam and PerkinElmer Sign Exclusive Licensing & R&D Collaboration Agreement for Photina® Technology Axxam, a science-driven biotechnology company focused on early-stage discovery research and services for the life science industry, and PerkinElmer, a global technology leader in Health Sciences and Photonics, have signed a global licensing agreement whereby PerkinElmer will become the exclusive provider of